Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
Hobbs FDR. et al, (2025), Health Technol Assess, 29, 1 - 130
Low-dose spironolactone and cardiovascular outcomes in moderate stage Chronic Kidney Disease: a randomised controlled trial
HOBBS R. et al, (2024), Nature Medicine
NHS reference costs: a history and cautionary note.
Amies-Cull B. et al, (2023), Health Econ Rev, 13
Systematic review of patients' and healthcare professionals' views on patient-initiated follow-up in treated cancer patients.
Dretzke J. et al, (2023), Cancer Med, 12, 16531 - 16547
Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting.
Kirby AM. et al, (2023), Clin Oncol (R Coll Radiol), 35, 347 - 350
Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol), 35, 301 - 310
The early use of Antibiotics for At-risk children with InfluEnza in Primary Care (the ARCHIE programme)
Wang K. et al, (2023), Programme Grants for Applied Research, 1 - 57
Protocol for the TRANSLATE prospective, multi-centre, randomised clinical trial.
Bryant RJ. et al, (2023), BJU Int
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Thomson DJ. et al, (2023), Clin Transl Radiat Oncol, 38, 147 - 154
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
Jones D. et al, (2022), HemaSphere, 6, 43 - 44
Estimating BMI distributions by age and sex for local authorities in England: a small area estimation study
Amies-Cull B. et al, (2022), BMJ Open, 12, e060892 - e060892
Small area estimates of BMI by age, sex and lower tier local authority (England)
Amies-Cull B. et al, (2022)
Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial.
Lorenc A. et al, (2022), Clin Oncol (R Coll Radiol), 34, 230 - 240